No doubt he had his pals lined up to short the stock, on the day he did that conference. If they covered the short that day, they did pretty well. If they trusted him and stayed short, they're all under water, as of Friday close. Good going guys, that'll teach you to trust a liar like brian.
Uncle, this is similar to ""Flagpole with Pennant"" which looks to be happening also... If it continues -- Price will go to $12.95 + $2.50 = $15.50.
The previous flagpole moves were $2.50 each time. It's very pronounced on a 7 month chart..
Well, got that close above resistance, there's 2 fib resistances before $12.95. First one is about $11.18, I'll do some math on the next one.
Opko Health ticks higher, article sees blockbuster potential for Rayaldy • 9:09 AM
• Opko Health (OPK) trades 2% higher before the bell.
• Helping the cause is SA contributor John Ford, who says Rayaldy "should be a blockbuster."
• "What will Rayaldy be worth in two years?" Ford asks, before saying that in his estimation, the total market potential is $16-24B annually.
Rayaldy's path to commercialization
OPKO expects to announce the topline clinical results for the pivotal phase 3 Rayaldy trials in mid-2014. The NDA (new drug application) will be filed (accepted for review) by the FDA in the first half of 2015.
The goals of the NDA are to provide enough information to permit FDA reviewers to establish the following:
· Is Rayaldy safe and effective in its proposed indication(s) when used as directed, and do the benefits of the drug outweigh the risks?
· Is Rayaldy's proposed labeling appropriate?
· Are the methods used in manufacturing Rayaldy and the controls used to maintain the drug's quality adequate to preserve the drug's identity, strength, quality and purity?
From there, we can expect about 10 months to FDA approval. Commercialization will rapidly follow, in early 2016 at the latest. However, given OPKO's global reach, we could see Rayaldy introduced into other markets before the U.S. launch.
The two most important events will be the announcement of topline phase 3 results and FDA approval. We could see a share price run-up in anticipation of each of these events as is often the case with biotech companies.
What will Rayaldy be worth in 2 years?
Rayaldy should be hitting the market by early 2016 and, as we approach that date, Rayaldy's value should increase substantially. The total market potential for this one drug is at least $16 billion annually, although I have seen figures as high as $24 billion. The variances in market potential are dependent on OPKO's ability to penetrate the market globally and to expand the approved indication through appropriate line extension strategies.
The potential market in the U.S. includes 2 to 4 million patients. Competitive prescription and over-the-counter (OTC) vitamin D repletion products have been recently proven (in numerous controlled clinical trials) to be ineffective in managing SHPT in chronic kidney disease. Competitive prescription vitamin D hormone replacement product
Until we get a CLOSE above $10.92 (bozo day), indicators won't tell you much. The MO players use those resistance lines..
but you do a lot of good here.. You helped me understand the company, back in June and I bought a lot of it.. Don't trade in and out, just waiting to see how it all comes out.